American Institute for Advanced Investment Management LLP Has $6.41 Million Stock Position in Cencora, Inc. $COR

Key Points

• American Institute for Advanced Investment Management LLP increased its stake in Cencora by 27% in Q4, buying 4,029 shares to hold 18,975 shares valued at $6,409,000, making it the fund's 4th-largest position (≈3.9% of its holdings).
• Institutional ownership of Cencora stands at 97.52% with Vanguard, State Street and JPMorgan among the largest holders, and analysts carry a "Moderate Buy" consensus (12 Buys, 2 Holds) with an average target of $398.17.

American Institute for Advanced Investment Management LLP lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 27.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,975 shares of the company's stock after buying an additional 4,029 shares during the period. Cencora accounts for approximately 3.9% of American Institute for Advanced Investment Management LLP's holdings, making the stock its 4th biggest position. American Institute for Advanced Investment Management LLP's holdings in Cencora were worth $6,409,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company's stock valued at $7,976,681,000 after buying an additional 221,570 shares during the last quarter. State Street Corp grew its position in shares of Cencora by 9.3% during the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company's stock valued at $2,872,249,000 after buying an additional 782,911 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Cencora by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company's stock valued at $1,461,965,000 after buying an additional 821,098 shares during the last quarter. Boston Partners grew its position in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company's stock valued at $1,409,152,000 after buying an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Cencora by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company's stock valued at $1,241,094,000 after buying an additional 115,278 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on COR. Barclays upped their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Jefferies Financial Group upgraded shares of Cencora from an "underperform" rating to a "buy" rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. upped their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded shares of Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, February 5th. Finally, Robert W. Baird set a $415.00 target price on shares of Cencora in a research report on Tuesday, January 13th. Twelve equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $398.17.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.38% of the stock is owned by company insiders.

Cencora Trading Up 0.0%

Cencora stock opened at $320.97 on Monday. The firm has a 50 day simple moving average of $345.36 and a 200-day simple moving average of $342.83. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The stock has a market capitalization of $62.44 billion, a PE ratio of 38.58, a price-to-earnings-growth ratio of 1.50 and a beta of 0.72. Cencora, Inc. has a 12-month low of $271.00 and a 12-month high of $377.54.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business's revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm posted $3.73 earnings per share. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora's dividend payout ratio (DPR) is 28.85%.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.